"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

In multiple myeloma, plasma cells make abnormal proteins that can't do their job right. Myelodysplastic syndrome (MDS): A type of cancer in which there are abnormal blood-forming cells in bone marrow.

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

As multiple myeloma research and development has progressed, our understanding of the science has unlocked the need to develop therapies that build on each other synergistically.

Multiple myeloma – a rare form of blood cancer – is usually found in people 65 and older. While it’s rare in young adults, a small percentage of people 19-40 also have the disease.